Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 4

3(50.0%)

Phase 2

2(33.3%)

N/A

1(16.7%)

6Total

Phase 4(3)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07557914Phase 2Not Yet Recruiting

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

Role: collaborator

NCT07483359Phase 2Not Yet Recruiting

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Role: collaborator

NCT07196657Not ApplicableRecruiting

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

Role: collaborator

NCT03024164Recruiting

Stroke Registration of Young Adults in China

Role: collaborator

NCT05028855Recruiting

Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis

Role: collaborator

NCT01938820Phase 4Completed

Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Role: collaborator

NCT01938781Phase 4Completed

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Role: collaborator

NCT01943617Phase 4Completed

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Role: collaborator

NCT03108794Unknown

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Role: collaborator

All 9 trials loaded